Bellerophon Therapeutics (BLPH) Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLPH, but not buy additional shares or sell existing shares.
View BLPH analyst ratings or view top-rated stocks.

3 analysts have issued twelve-month price targets for Bellerophon Therapeutics' shares. Their BLPH share price forecasts range from $2.00 to $2.00. On average, they anticipate the company's share price to reach $2.00 in the next twelve months. This suggests a possible upside of 420.6% from the stock's current price.
View analysts price targets for BLPH or view top-rated stocks among Wall Street analysts.

Bellerophon Therapeutics' stock was trading at $0.90 at the beginning of 2023. Since then, BLPH shares have decreased by 57.3% and is now trading at $0.3842.
View the best growth stocks for 2023 here.

Bellerophon Therapeutics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 197,500 shares, an increase of 59.8% from the August 31st total of 123,600 shares. Based on an average trading volume of 193,800 shares, the days-to-cover ratio is presently 1.0 days.
View Bellerophon Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our BLPH earnings forecast.

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) issued its quarterly earnings results on Monday, August, 14th. The biotechnology company reported ($0.42) earnings per share for the quarter.

Bellerophon Therapeutics's stock reverse split before market open on Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX).

(BLPH) raised $60 million in an initial public offering on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Shares of BLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLPH stock can currently be purchased for approximately $0.38.

Bellerophon Therapeutics (NASDAQ:BLPH) has a market capitalization of $4.70 million. The biotechnology company earns $-19,830,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis.

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The official website for the company is www.bellerophon.com. The biotechnology company can be reached via phone at (908) 574-4770 or via email at btinvestorrelations@bellerophon.com.